Ratings Editas Medicine, Inc.

Equities

EDIT

US28106W1036

Real-time Estimate Cboe BZX Other stock markets 03:52:17 2024-06-10 pm EDT			5-day change	1st Jan Change
5.295 ^USD	-0.09%		-2.50%	-47.93%

May. 30	Evercore ISI Cuts Price Target on Editas Medicine to $7 From $15, Maintains In Line Rating	MT
May. 14	Editas Medicine Insider Bought Shares Worth $253,868, According to a Recent SEC Filing	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Over the past year, analysts have regularly revised upwards their sales forecast for the company.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The opinion of analysts covering the stock has improved over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
Based on current prices, the company has particularly high valuation levels.
The company appears highly valued given the size of its balance sheet.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
EDITAS MEDICINE, INC.	-47.93%	436M	C+
MODERNA, INC.	+49.58%	57.87B	B-
LONZA GROUP AG	+41.65%	40.25B	A
IQVIA HOLDINGS INC.	-6.97%	39.94B	B
CELLTRION, INC.	-5.96%	28.54B	C
ICON PUBLIC LIMITED COMPANY	+12.96%	26.4B	B-
ALNYLAM PHARMACEUTICALS, INC.	-19.81%	19.33B	B
MEDPACE HOLDINGS, INC.	+31.80%	12.4B	C+
BIO-TECHNE CORPORATION	+0.34%	12.23B	B+
UNITED THERAPEUTICS CORPORATION	+25.36%	12.2B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes